| Application no. and date | 03748439.1 (espacenet) (Federated) (European Patent Register), 20030815 | | Patent/reg. no. and date | DK/EP 1528933, 20120502 | | Publication date | 20050511 | | Priority no. and date | US 222140, 20020816 | | EP pub. no. and date |
EP 1528933 20050511 | | Effective date | | | Applicant/owner | AbbVie Biotechnology Ltd., Clarendon House,
2 Church Street
HM 11 Hamilton, BM | | Applicant ref. no. | P81202905DK00E | | Inventor | DICKES, Michael, Schafergasse 58
67127 Rodersheim-Gronau, DE,
KRAUSE, Hans-Juergen, Marie-Curie-Weg 1
68647 Biblis, DE,
BAUST, Lisa, Goethestr. 15a
67063 Ludwigshafen, DE | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 39/395 (2006.01) , A61K 47/26 (2006.01) , A61K 9/19 (2006.01) | | Title | Farmaceutisk anti-TNF-alpha-antistofformulering | | Int. application no. | IB2003004502 | | Int. publication no. | WO2004016286 | | Related patent (certificate) | | | Status | Ophævet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
